TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38110376

Group type: EXPERIMENTAL
Intervention: Care cOORDInatioN And sympTom managEment (COORDINATE) intervention
Number of subjects: 0
Study: 38110389

Group type: EXPERIMENTAL
Intervention: NSTEMI patients
Number of subjects: 8277

Group type: COMPARATOR
Intervention: STEMI patients
Number of subjects: 8277
Study: 38110392

Group type: EXPERIMENTAL
Intervention: Nutrition supplementation plus standard of care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cash transfer plus standard of care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study: 38110561

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day for 21-28 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 61
Study: 38110580

Group type: EXPERIMENTAL
Intervention: ePOCT+
Number of subjects: 44306
Study: 38110653

Group type: EXPERIMENTAL
Intervention: Teclistamab
Number of subjects: 165
Study: 38110665

Group type: EXPERIMENTAL
Intervention: Cadonilimab 15 mg/kg Q3W plus anlotinib
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cadonilimab 10 mg/kg Q3W plus anlotinib
Number of subjects: 69
Study: 38110790

Group type: EXPERIMENTAL
Intervention: Minzasolmin (UCB0599); orally administered small molecule inhibitor of ASYN misfolding; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-methyl labeled PET tracer; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 38110851

Group type: EXPERIMENTAL
Intervention: Perinatal sleep difficulties
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: 8-year follow-up
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Severity of depressed mood
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Socioeconomic and environmental factors
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Longitudinal relationship
Number of subjects: 1238
Study: 38110885

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and daclatasvir for 12 weeks (extended to 24 weeks for those with cirrhosis)
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and daclatasvir treatment
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Screening for new HCV infections 12 months later
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Questionnaires assessing risk factors, productivity, health care usage, and quality of life
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Retesting patients who completed treatment 12 months later
Number of subjects: 25000
Study: 38110901

Group type: EXPERIMENTAL
Intervention: HIP1601 (dual delayed-release esomeprazole) 40 mg
Number of subjects: 213

Group type: COMPARATOR
Intervention: HGP1705 (delayed-release esomeprazole) 40 mg
Number of subjects: 213
Study: 38110921

Group type: EXPERIMENTAL
Intervention: Maternal prepregnancy BMI ≥ 25 kg/m²
Number of subjects: 24294

Group type: COMPARATOR
Intervention: BMI reference group (control)
Number of subjects: 24294
Study: 38110922

Group type: EXPERIMENTAL
Intervention: Aquatic exercise program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard care exercise
Number of subjects: 34
Study: 38110937

Group type: EXPERIMENTAL
Intervention: Digitally 3D-printed ocular prostheses (DG, n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional PMMA ocular prostheses (CG, n=11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (DG and CG)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 3D-printed acrylic resin (DG)
Number of subjects: 22
Study: 38110979

Group type: EXPERIMENTAL
Intervention: Standard implementation approach (online training, live webinar, resource website)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Virtual facilitation approach (provided by a trained facilitator)
Number of subjects: 30
Study: 38110997

Group type: EXPERIMENTAL
Intervention: Training on de-escalation of violence and a code of conduct informed through participatory citizen science research
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Training on de-escalation of violence and a code of conduct
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness study comparing the two strategies
Number of subjects: 11
Study: 38111533

Group type: EXPERIMENTAL
Intervention: Pomalidomide + Velcade + Dexamethasone (PVd)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Velcade + Dexamethasone (Vd)
Number of subjects: 186
Study: 38111608

Group type: EXPERIMENTAL
Intervention: EmbracePlus wristband
Number of subjects: 15
Study: 38111676

Group type: EXPERIMENTAL
Intervention: Single-belt treadmill mode at comfortable walking speed (CWS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Split-belt treadmill mode with backward-directed resistance
Number of subjects: 18
Study: 38111699

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 0.2% flushing of suctioning catheters after every endotracheal suction procedure
Number of subjects: 136

Group type: COMPARATOR
Intervention: Normal saline or distilled water flushing of suctioning catheters
Number of subjects: 136
Study: 38111750

Group type: EXPERIMENTAL
Intervention: Casirivimab and imdevimab
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: High viral loads (∼6.0 log)
Number of subjects: 1069
Study: 38111886

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) during AC including the provision of an activity tracker
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (EXpostAC) received an activity tracker only
Number of subjects: 57
Study: 38111994

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention programme
Number of subjects: 297

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 297
Study: 38112484

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.4 mg
Number of subjects: 251
Study: 38112493

Group type: EXPERIMENTAL
Intervention: Modified rooms
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard rooms
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Light intensity
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Differences in serum melatonin
Number of subjects: 74
Study: 38112645

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids used as an adjunct to antimicrobial therapy for herpetic keratitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids used as an adjunct to antimicrobial therapy for bacterial keratitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids for advanced bacterial corneal ulcers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids for fungal keratitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids for acanthamoeba keratitis
Number of subjects: 0
Study: 38112724

Group type: EXPERIMENTAL
Intervention: Novel therapeutic intervention
Number of subjects: 0
Study: 38112795

Group type: EXPERIMENTAL
Intervention: Generic pomalidomide (4 mg daily on days 1-21) plus low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22; 20 mg for patients aged > 75 years)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Generic pomalidomide plus low-dose dexamethasone
Number of subjects: 85
Study: 38112814

Group type: EXPERIMENTAL
Intervention: AI model predictions without explanations
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: AI model predictions with explanations
Number of subjects: 457

Group type: COMPARATOR
Intervention: Systematically biased AI model predictions
Number of subjects: 457

Group type: COMPARATOR
Intervention: Biased AI model predictions with explanations
Number of subjects: 457
Study: 38112922

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg, twice daily)
Number of subjects: 256
Study: 38113009

Group type: EXPERIMENTAL
Intervention: Personalized plan (PP) with personalized home-delivered meals and behavioral change messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with non-personalized meals and messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalized plan (PP)
Number of subjects: 0
Study: 38113022

Group type: EXPERIMENTAL
Intervention: Quantum Molecular Resonance (QMR) treatment, 4 sessions at 1-week intervals.
Number of subjects: 81

Group type: COMPARATOR
Intervention: SH-TH group (control group).
Number of subjects: 81
Study: 38113093

Group type: EXPERIMENTAL
Intervention: Relational savoring (RS) intervention for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 80
Study: 38113103

Group type: EXPERIMENTAL
Intervention: DrinksRation smartphone app intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: UK Chief Medical Officer guidance on alcohol consumption (control)
Number of subjects: 0
Study: 38113102

Group type: EXPERIMENTAL
Intervention: Kirabo SMS text message intervention
Number of subjects: 200
Study: 38113421

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with maximum tumor RNA disruption index (RDI) values
Number of subjects: 454
Study: 38113446

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/day)
Number of subjects: 15804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15804

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/day) in participants with <12 ng/mL and denied taking concurrent vitamin D
Number of subjects: 15804

Group type: COMPARATOR
Intervention: Placebo in participants with <12 ng/mL and denied taking concurrent vitamin D
Number of subjects: 15804
Study: 38113459

Group type: EXPERIMENTAL
Intervention: Parsaclisib 20 mg once daily for 8 weeks then 2.5 mg once daily (daily dosing group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Parsaclisib 20 mg once daily for 8 weeks then 20 mg once weekly (weekly dosing group)
Number of subjects: 100
Study: 38113470

Group type: EXPERIMENTAL
Intervention: venetoclax-R2 (venetoclax 600 mg daily after ramp-up, lenalidomide 20 mg daily for days 1 to 21, rituximab 375 mg/m2 weekly for 4 weeks then every 8 weeks)
Number of subjects: 59
Study: 38113483

Group type: EXPERIMENTAL
Intervention: Dietary intervention involving traditional marine foods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group consuming sucrose- and starch-rich foods
Number of subjects: 0
Study: 38113746

Group type: EXPERIMENTAL
Intervention: ICU-treated patients
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ward-treated patients
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Home-isolated COVID-19 patients
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-COVID-19 controls
Number of subjects: 69
Study: 38113919

Group type: EXPERIMENTAL
Intervention: Trauma exposure
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PTSD symptoms
Number of subjects: 96
Study: 38114046

Group type: EXPERIMENTAL
Intervention: On-site cardiac rehabilitation followed by 12 weeks of telerehabilitation
Number of subjects: 40

Group type: COMPARATOR
Intervention: On-site cardiac rehabilitation followed by standard homecare and exercise programme
Number of subjects: 40
Study: 38114277

Group type: EXPERIMENTAL
Intervention: Catheterisation with a needle guide (n=150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Catheterisation without a needle guide (n=150)
Number of subjects: 300
Study: 38114357

Group type: EXPERIMENTAL
Intervention: Mobocertinib
Number of subjects: 228

Group type: COMPARATOR
Intervention: Amivantamab
Number of subjects: 228
Study: 38114507

Group type: EXPERIMENTAL
Intervention: 3D printed personalized liver models based on self-healing elastomers
Number of subjects: 5
Study: 38114518

Group type: EXPERIMENTAL
Intervention: Durvalumab plus stereotactic radiation (DRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Durvalumab monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment arms (combined)
Number of subjects: 0
Study: 38114596

Group type: EXPERIMENTAL
Intervention: Intrathecal infusion of autologous bone marrow mononuclear cells (BMMNCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: CP patients
Number of subjects: 0
Study: 38114624

Group type: EXPERIMENTAL
Intervention: CFI-400945 at doses ranging from 64 mg/day to 128 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CFI-400945
Number of subjects: 13
Study: 38114718

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue (NA) therapy cessation
Number of subjects: 57
Study: 38114794

Group type: EXPERIMENTAL
Intervention: Oral glutamine supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (sex- and age-matched)
Number of subjects: 9
Study: 38114867

Group type: EXPERIMENTAL
Intervention: Elevated Body Mass Index (BMI)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 147
Study: 38114941

Group type: EXPERIMENTAL
Intervention: Frontal BIS sensor position
Number of subjects: 12

Group type: COMPARATOR
Intervention: Post-auricular BIS sensor position
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both sensor positions
Number of subjects: 12
Study: 38114952

Group type: EXPERIMENTAL
Intervention: Action Observation (AO) therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (observing a natural landscape)
Number of subjects: 60
Study: 38114958

Group type: EXPERIMENTAL
Intervention: Corega Ultra denture fixative cream (GlaxoSmithKline)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Olivafix (Bonyf)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sea.Bond adhesive strips (Sea.Bond)
Number of subjects: 64
Study: 38114979

Group type: EXPERIMENTAL
Intervention: Bis-GMA-free resin composite (Admira fusion x-tra)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bis-GMA containing resin composite (x-tra fil)
Number of subjects: 20
Study: 38115002

Group type: EXPERIMENTAL
Intervention: RTS,S vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: primaquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotyping methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early phase power calculations
Number of subjects: 0
Study: 38115004

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 38115038

Group type: EXPERIMENTAL
Intervention: Intra-operative HMW microdialysis
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lactate-containing perfusate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Albumin-containing perfusate
Number of subjects: 14
Study: 38115195

Group type: EXPERIMENTAL
Intervention: Nivolumab s.c. 720, 960, or 1,200 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nivolumab i.v. 3 mg/kg every 2 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nivolumab i.v. 10 mg/kg every 2 weeks
Number of subjects: 82
Study: 38115208

Group type: EXPERIMENTAL
Intervention: Itacitinib (300 mg once daily) plus pembrolizumab (200 mg every 3 weeks)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Parsaclisib (10 mg once daily in Part 1; 0.3 mg once daily in Part 2) plus pembrolizumab (200 mg every 3 weeks)
Number of subjects: 159
Study: 38115209

Group type: EXPERIMENTAL
Intervention: Tozorakimab (subcutaneous or intravenous)
Number of subjects: 88
Study: 38115745

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 38116040

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dorsal penile nerve block (DPNB) with sedation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no ultrasound-guided DPNB)
Number of subjects: 70
Study: 38116137

Group type: EXPERIMENTAL
Intervention: Isotoxic dose escalation to 75 Gy in 30 fractions with concurrent bevacizumab (BEV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference plan (not specified in detail)
Number of subjects: 10
Study: 38116535

Group type: EXPERIMENTAL
Intervention: Robotic-assisted percutaneous coronary intervention (RA-PCI) using the CorPath GRX Vascular Robotic System
Number of subjects: 21
Study: 38116638

Group type: EXPERIMENTAL
Intervention: Tirbanibulin 1% ointment applied once daily for 5 consecutive days
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Tirbanibulin 1% ointment
Number of subjects: 702
Study: 38116642

Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg) administered intravenously 16 times over 6 months
Number of subjects: 139
Study: 38116658

Group type: EXPERIMENTAL
Intervention: Resected lymph nodes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38116670

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting postoperative soiling
Number of subjects: 601
Study: 38116674

Group type: EXPERIMENTAL
Intervention: Transection of the pulmonary branches of the vagus nerve
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sham procedure (control group)
Number of subjects: 116
Study: 38116682

Group type: EXPERIMENTAL
Intervention: Kynurenine/tryptophan above 0.067 µM/µM
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: LPC18:2/PCa36:2 below the cut-off 0.084 µM/µM
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Hexadecanoylcarnitine below 0.093 µM
Number of subjects: 146
Study: 38117424

Group type: EXPERIMENTAL
Intervention: Mixed phenotype ATTR amyloidosis
Number of subjects: 1185
Study: 38117449

Group type: EXPERIMENTAL
Intervention: Incentive (n=52)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual Care (n=50)
Number of subjects: 102
Study: 38117500

Group type: EXPERIMENTAL
Intervention: Daily-delivered meals
Number of subjects: 243

Group type: COMPARATOR
Intervention: Drop-shipped frozen meals
Number of subjects: 243
Study: 38117499

Group type: EXPERIMENTAL
Intervention: Electronic nudges (9 different nudge letters)
Number of subjects: 964870

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 964870

Group type: EXPERIMENTAL
Intervention: Electronic nudges (cardiovascular benefits letter)
Number of subjects: 964870

Group type: EXPERIMENTAL
Intervention: Electronic nudges (repeated letter)
Number of subjects: 964870
Study: 38117526

Group type: EXPERIMENTAL
Intervention: PF-07038124, 0.01%, topical ointment once daily for 6 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Vehicle, topical ointment once daily for 6 weeks
Number of subjects: 104
Study: 38117527

Group type: EXPERIMENTAL
Intervention: Oral midazolam 3.75 mg
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study: 38117554

Group type: EXPERIMENTAL
Intervention: Food-insecure cohort (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Food-secure cohort (n=30)
Number of subjects: 60
Study: 38117578

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no acupressure)
Number of subjects: 0
Study: 38117792

Group type: EXPERIMENTAL
Intervention: Healthcare-associated sources including patient-to-patient transmission and/or acquisition from healthcare environmental dust and/or water biofilms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthcare environmental dust and water biofilm NTM isolates that are genetically highly-related to respiratory isolates.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common home of residence watersheds among pwCF infected with clustered isolates.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Characterization of healthcare-associated transmission and/or acquisition modes and settings.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incidence and prevalence of healthcare-associated environmental NTM species/subspecies by geographical region.
Number of subjects: 0
Study: 38118022

Group type: EXPERIMENTAL
Intervention: Doxycycline PEP (200 mg taken within 72 hours after condomless sex)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Doxycycline PEP
Number of subjects: 449
Study: 38118247

Group type: EXPERIMENTAL
Intervention: Nitrous oxide during intensive physiotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham gas during intensive physiotherapy (placebo)
Number of subjects: 75
Study: 38118246

Group type: EXPERIMENTAL
Intervention: Calf only (C)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Thigh and calf (TC)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Buttock and calf (BC)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Buttock, thigh, and calf (BTC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 105
Study: 38118249

Group type: EXPERIMENTAL
Intervention: PRT543 35 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PRT543 45 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PRT543
Number of subjects: 56
Study: 38118406

Group type: EXPERIMENTAL
Intervention: CAR T cells targeting CD19 and B cell maturation antigen (BCMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of CART-BCMA and CART-19
Number of subjects: 0
Study: 38122865

Group type: EXPERIMENTAL
Intervention: Berotralstat 150 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Berotralstat
Number of subjects: 81
Study: 38122893

Group type: EXPERIMENTAL
Intervention: OBE MASL
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: OBE MASH
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: OBE MASL and OBE MASH
Number of subjects: 8
Study: 38123024

Group type: EXPERIMENTAL
Intervention: Psyllium fiber, n = 39, for 6 weeks
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo, n = 49, for 6 weeks
Number of subjects: 209
Study: 38123124

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 88
Study: 38123352

Group type: EXPERIMENTAL
Intervention: Soticlestat 300 mg + Itraconazole
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Soticlestat 300 mg + Mefenamic acid
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Soticlestat 300 mg + Rifampin
Number of subjects: 43
Study: 38123459

Group type: EXPERIMENTAL
Intervention: SLEDAI-2K score ≥10
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: IFNGS-high
Number of subjects: 823

Group type: COMPARATOR
Intervention: IFNGS-low
Number of subjects: 823